Sorrento Therapeutics, which was found using the ticker (SRNE), now has a total of 2 analysts covering the stock. The consensus rating is “Buy”. The range between the high target price and the low target price is between 30 and 21, where we calculate the average price we see 25.5. Given the shares’ previous closing price at 7.61, this would indicate a potential upside of 235.1%. The 50 day moving average is 7.26 and the 200 day moving average is 8.22. The company’s market capitalization is $ 1,976 million. Visit the company’s website at: http://www.sorrentotherapeutics.com
Sorrento Therapeutics, a clinical-stage biopharmaceutical company, develops therapies for cancer, autoimmune diseases, inflammatory and neurodegenerative diseases. It operates in two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics using its proprietary G-MAB antibody library and targeted delivery modalities, including chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody-drug conjugates and bispecific antibodies -Approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company’s clinical programs under development include an anti-CD38 CAR-T therapy for the treatment of multiple myeloma, amyloidosis and graft-versus-host diseases. It is also developing resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of late-stage cancer and knee pain in osteoarthritis; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company is also developing SEMDEXA, an injectable viscous gel formulation, a phase III study for the treatment of sciatica, a pathology of lower back pain; and SP-103, a non-aqueous topical lidocaine system in clinical development for chronic back pain. It has various collaborations with SmartPharm Therapeutics Inc. to develop a gene-encoded antibody vaccine to protect against COVID-19; Cellularity for Entering Phase I / II Clinical Trials in Up to 86 Patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy against SARS-CoV-2 infection, and a research test agreement with the University of Texas Medical Branch at Galveston for preclinical testing of Sorrento’s therapeutic COVID-19 product candidates. The company was founded in 2006 and is based in San Diego, California.
You can now share this on Stocktwits, just click on the logo below and insert the ticker into the text you can see.